Clinical Validation

Discover Our Latest

Published Data for
PredictSURE® IBD

The IBD biomarker was originally discovered using gene expression analysis of CD8+ T cells (Lee 2011, McKinney 2015) and subsequently translated into a 17 gene (15 informative, 2 control genes) whole blood qPCR test, validated on an independent cohort of 123 IBD patients (66 CD, 57 UC) (Biasci 2019).

Our test

Click image to enlarge

Patients identified as high-risk experienced a more aggressive disease course characterised by:

  • Shorter time to treatment escalation; hazard ratio (HR) 2.65 for CD and 3.12 for UC (Fig. 1 A,B)
  • Increased risk of any treatment escalation; relative risk (RR) at 12 months 1.7 for CD, 2.8 for UC (Fig. 1 C,D)
  • Increased risk of multiple treatment escalation
  • Need for more potent therapies to achieve disease remission

    Figure 1 (A,B) Treatment-free survival for Crohn’s disease and ulcerative colitis; P= log-rank test. HR: hazard ratio. (C,D) Stacked density plots demonstrating maximum medical therapy required over 2.5 years follow up in high and low-risk sub-groups for CD and UC. Data censored at maximum follow-up for each patient (Biasci 2019).

PredictSURE IBD test clinical validation

Results based on validation in a cohort of patients independent from the discovery cohort

1. PredictSURE IBD Clinical Validation (PredictSURE IBD IFU, see Biasci et al. 2019 for longer term follow up)
*in the first 12 months of follow up

PredictSURE IBD validation study –

A blood-based prognostic biomarker in IBD